Fig. 6.
CD4−CD8− splenocytes act synergistically with CD8 T cells to augment GVL effects in vivo.
Survival is shown for mice that received 500 EL4 cells and 5 × 106 TCD WT BALB/c BMCs along with 8.5 × 106 CD4-depleted (●; n = 7), 1.4 × 106 CD8+ (♦; n = 7), 7.1 × 106 TCD (▴; n = 7), or 1.4 × 106 CD8+ and 7.1 × 106TCD (▾; n = 7) WT BALB/c splenocytes. Syngeneic controls receiving 5 × 106 TCD B6 BMCs (■; n = 5) or 5 × 106 B6 BMC plus 500 EL4 cells (▪; n = 5) are indicated. FACS analysis revealed that CD4-depleted splenocytes contained 16.5% CD8+ and 83.5% CD4−CD8− cells, so the actual numbers of BALB/c CD8+ and CD4−CD8−splenocytes given to the recipients of 8.5 × 106CD4-depleted BALB/c splenocytes were 1.4 × 106 and 7.1 × 106, respectively.
